Expanded Access Program for Bezuclastinib and Sunitinib in GIST Patients
Cogent Biosciences is initiating an expanded access program for bezuclastinib to be used with sunitinib in GIST patients.
Asset / Drug
Drug and asset intelligence for bezuclastinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.